The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade
Open Access
- 1 April 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (7), 2886-2893
- https://doi.org/10.1182/blood-2002-10-3014
Abstract
We recently developed a murine protocol for the induction of allogeneic mixed chimerism and tolerance employing nonmyeloablative total body irradiation (TBI), standard-dose bone marrow transplantation (BMT), and costimulation blockade (cobl) with an anti-CD154 monoclonal antibody (mAb) plus CTLA4Ig. We now evaluated whether a short course (1 month) of immunosuppressive drugs, which would be ethically required in the clinical setting of organ transplantation to prevent graft loss in case tolerance is not achieved, interferes with tolerance induced with this regimen. Our results show that calcineurin inhibitors (cyclosporin A [CyA] or tacrolimus [FK]) inhibit development of long-term chimerism and abrogate tolerance induction in this model. Rapamycin (rapa), methylprednisolone (MP), FTY720, and mycophenolate mofetil (MMF), in contrast, have no negative effect on chimerism or tolerance development. Peripheral deletion of donor-reactive T cells, which usually occurs in the weeks following BMT in this model, is blocked by CyA and FK, but not by the other drugs tested. Furthermore, we found that the additional use of compatible immunosuppressive drugs (rapa plus MMF plus MP) allows the dose of TBI to be reduced, so that mixed chimerism and donor skin-graft acceptance can be achieved with 1 Gy using clinically feasible cell numbers. Thus, this protocol of BMT with costimulation blockade can be safely combined with a clinically tested immunosuppressive regimen to permit success with a lower dose of irradiation. These results should facilitate clinical application of this tolerance strategy.Keywords
This publication has 46 references indexed in Scilit:
- Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditionsBlood, 2002
- WHAT ROLE FOR FTY720, A NOVEL IMMUNOSUPPRESSIVE AGENT, IN CANINE NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION?1Transplantation, 2002
- Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantationThe Lancet, 1999
- RECOMMENDATIONS OF THE EXPERT PANEL ON ETHICAL ISSUES IN CLINICAL TRIALS OF TRANSPLANT TOLERANCETransplantation, 1998
- Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwaysNature, 1996
- Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus MonkeysTransplantation, 1995
- The genetic basis of negative selection of Tcrb-Vll+ T cellsImmunogenetics, 1991
- Genes encoding ligands for deletion of Vβ11 T cells cosegregate with mammary tumour virus genomesNature, 1991
- Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.The Journal of Experimental Medicine, 1989
- Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.The Journal of Experimental Medicine, 1989